Showing 1 to 1 of 1 results
forbes.com
🌐 85% Global Worthiness
CMS Drug Price Controls Under IRA Threaten Pharmaceutical Innovation
CMS announced price negotiations for 15 drugs under the IRA, imposing penalties up to 95% of U.S. sales for non-compliance; this discourages R&D, potentially resulting in fewer new drugs and harming patients, with studies projecting a loss of 135 new drugs and $663 billion in R&D spending by 2039.
CMS Drug Price Controls Under IRA Threaten Pharmaceutical Innovation
CMS announced price negotiations for 15 drugs under the IRA, imposing penalties up to 95% of U.S. sales for non-compliance; this discourages R&D, potentially resulting in fewer new drugs and harming patients, with studies projecting a loss of 135 new drugs and $663 billion in R&D spending by 2039.
Progress
60% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results